NCAB ad hoc working group seeks to define its role as it approves eight reissue concepts “We could do a lot more than be another committee to check the RFAs before they go to the next level.”

NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises
New NOFO aims to shrink applications by 40%

Late next month, NCI is expected to publish the new criteria it uses to bestow designations on America’s network of cancer centers.

Dinah Singer retires from NCI, remains at NIH as Scientist Emeritus

Dinah S. Singer is now an NIH Scientist Emeritus after retiring from NCI in June.

October 30, 2026

Vol.52 No.40

In Brief

University of Illinois’ Andrei Gartel receives NCI grant to study AML

NCI awarded a two-year $422,000 grant to University of Illinois Cancer Center member Andrei Gartel to examine what might influence differences in outcomes for some patients with acute myeloid leukemia, an aggressive blood cancer with persistently poor outcomes in which relapse is common.

October 30, 2026

Vol.52 No.40

In Brief

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

A University of Oklahoma physician-researcher recently received $2.9 million in funding from NCI to study whether RedHill Biopharma’s drug opaganib, given after CAR T-cell therapy, can help the immune cells fight cancer more effectively.

October 23, 2026

Vol.52 No.39

Cancer Policy

Letai announces: NCI met FY26 goal of full funding payout

In a post on NCI’s LinkedIn, NCI Director Anthony Letai confirmed that the institute has fully awarded and paid out all of its grant funding for the Fiscal Year 2026.

October 16, 2026

Vol.52 No.38

By Claire Marie Porter

Podcast

As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”

As the oncology community waits with bated breath for a possible FDA approval of GRAIL’s Galleri test, NCI Director Anthony Letai has a lot to say about multi-cancer detection tests—particularly Galleri.

October 14, 2026

NCAB ad hoc working group seeks to define its role as it approves eight reissue concepts

“We could do a lot more than be another committee to check the RFAs before they go to the next level.”

YOU MAY BE INTERESTED IN

NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises
New NOFO aims to shrink applications by 40%

Dinah Singer retires from NCI, remains at NIH as Scientist Emeritus

University of Illinois’ Andrei Gartel receives NCI grant to study AML

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

Letai announces: NCI met FY26 goal of full funding payout

As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”

Renew today!

Subscriber content

Never miss an issue!

Login

NCAB ad hoc working group seeks to define its role as it approves eight reissue concepts

“We could do a lot more than be another committee to check the RFAs before they go to the next level.”

YOU MAY BE INTERESTED IN

NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprisesNew NOFO aims to shrink applications by 40%

Dinah Singer retires from NCI, remains at NIH as Scientist Emeritus

University of Illinois’ Andrei Gartel receives NCI grant to study AML

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

Letai announces: NCI met FY26 goal of full funding payout

As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”

Never miss an issue!

Login

NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises
New NOFO aims to shrink applications by 40%